Indian Pharma IP Trends: Biophore’s Patent Strategy, Oral Semaglutide SNAC Battles & Lenacapavir Oppositions
Biophore India Pharmaceuticals: Generic Patent Filing Strategy (2024–2026) Between October 2024 and November 2026, Biophore India Pharmaceuticals published 28 patent families—matching industry giant Cipla’s filing volume during the same timeframe despite operating at a much smaller revenue scale . Rather than pursuing new chemical entities, Biophore’s intellectual property portfolio functions as a targeted generic-launch pipeline designed to secure early market entry and freedom to operate . Portfolio Breakdown: Over half (54%, or 15 families) protect active pharmaceutical ingredient (API) manufacturing processes, 25% (7 families) cover finished formulations, and 21% (6 families) claim solid forms or salts . Therapeutic Focus: Filings prioritise central nervous system (CNS) disorders (7 families), rare diseases (7 families), and oncology (6 families) . High-Value Targets: Biophore has layered multiple patents around niche US-approved drugs (2021–2023) such as elacest...